This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Hewlett E , Toma M , Sullivan-Reed K , Gordo J , Sliwinski T , Tulin A , Childers WE , Skorski T
Novel allosteric PARP1 inhibitors for the treatment of BRCA-deficient leukemia
Med Chem Res. 2020 Jun;29(6) :962-978
PMID: 33071527 PMCID: PMC7560981
AbstractThe successful use of PARP1 inhibitors like olaparib (Loparza(®)) in the treatment of BRCA1/2- deficient breast cancer has provided clinical proof of concept for applying personalized medicine based on synthetic lethality to the treatment of cancer. Unfortunately, all marketed PARP1 inhibitors act by competing with the cofactor NAD(+) and resistance is already developing to this anti-cancer mechanism. Allosteric PARP1 inhibitors could provide a means of overcoming this resistance. A high throughput screen performed by Tulin et al. identified 5F02 as an allosteric PARP inhibitor that acts by preventing the enzymatic activation of PARP1 by histone H4. 5F02 demonstrated anti-cancer activity in several cancer cell lines and was more potent than olaparib and synergistic with olaparib in these assays. In the present study we explored the structure-activity relationship of 5F02 by preparing analogs that possessed structural variation in four regions of the chemical scaffold. Our efforts led to lead molecule 7, which demonstrated potent anti-clonogenic activity against BRCA-deficient NALM6 leukemia cells in culture and a therapeutic index for the BRCA-deficient cells over their BRCA-proficient isogenic counterparts.
Notes1554-8120 Hewlett, Elizabeth Toma, Monika Sullivan-Reed, Katherine Gordo, John Sliwinski, Tomasz Tulin, Alexei Childers, Wayne E Skorski, Tomasz R01 CA186238/CA/NCI NIH HHS/United States Journal Article Med Chem Res. 2020 Jun;29(6):962-978. doi: 10.1007/s00044-020-02537-0. Epub 2020 Apr 19.